Holy shit $DCTH I thought I was bullish modeling $29.5-31.5 M.
Lol imagine if that litigation based fund liquidated their $NKTR holdings at a loss based on a single jury question and then the jury rules very favorably to NKTR. Talk about throwing out all your prior work at the 5 yard line.
1
7
1,396
$NKTR where’s it go on a truly hung jury where…
Some not convinced LLY did wrong
Some say liable but not convinced on any damages
Some believe in sizeable damages
1
5
1,182
The big question is if $MRNA learned its lesson and goes shopping with this windfall. Or maybe they just blow it again.
1
141
$TENX wth happened to our deer dragging marathon running cave digging patients?
1
3
908
$REPL 10-to-3 in favor
$REPL Surprised the stock is down on this briefing doc. They’re basically setting up for the situation described below.
The voting question is: “Are the efficacy results from IGNYTE evaluable and clinically meaningful?”
Pretty low bar. They want it to get torn up in discussion but voted yes.
2
1,031
$REPL Surprised the stock is down on this briefing doc. They’re basically setting up for the situation described below.
The voting question is: “Are the efficacy results from IGNYTE evaluable and clinically meaningful?”
Pretty low bar. They want it to get torn up in discussion but voted yes.
$REPL AdCom prediction:
This will be a repeat of the 2nd $AMLX adcom; statisticians and experts will tear the trial apart. But they’ll vote yes to a softball question they’re being asked to provide cover for the pending approval.
The FDA is not going to go through all of this to reject it a third time, especially after Trump involvement. Plus, the adcom is scheduled right before pdufa… labeling talks will already be ongoing.
$REPL AdCom prediction:
This will be a repeat of the 2nd $AMLX adcom; statisticians and experts will tear the trial apart. But they’ll vote yes to a softball question they’re being asked to provide cover for the pending approval.
The FDA is not going to go through all of this to reject it a third time, especially after Trump involvement. Plus, the adcom is scheduled right before pdufa… labeling talks will already be ongoing.
I have no idea how $LRMR will pan out. But in this bull tape, with that much short interest, being long into the readout at these prices seems like a no brainer.
2
6
1,287
Where does $NVO go on another liver adverse event report from Foundayo? Are monthly OTM calls worth it for potential upside?
270
$XBI Ultimately Makary was his own worst enemy. Often said the right things, but the implementation was reckless and guided by academic dogma rather than a diligent and structured assessment balancing patient needs and prior commitments. $QURE $REPL wsj.com/health/healthcare/tr…
I do think AXS-05 has a >50% chance of approval. But I also think the FDA’s recent data quirks likely have some spill over to CDER. Market doesn’t appear to be pricing in the potential for rejection. Puts are probably at a price worth buying for the downside surprise. $AXSM
1
742
JUST IN : CANADIAN PRIME MINSTER MARK CARNEY TO ANNOUNCE CANADA’S FIRST EVER SOVEREIGN WEALTH FUND
THE FUND WILL BE CALLED “STRONG CANADA FUND” AND WILL FINANCE MAJOR NATIONAL INTEREST PROJECTS AND WORK ALONGSIDE THE PRIVATE SECTOR
ANYONE WILL BE ABLE TO INVEST IN THE FUND
$IDYA I’m just not convinced a huge DCR means much in an open label trial. I can’t even find a protocol for what time points were used to define SD/DCR.
And now they’re dropping good news like there’s no tomorrow. Multiple trial starts, AZN partnership.
I wonder if OptimUM-2 shows lackluster results. And if so, is $DCTH going to react positively? I don’t understand DCTH price action, at all - so perhaps this is the underappreciated overhang…?
1
511







